Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression

NCT: NCT05842291 · SUSPENDED

NCT IDNCT05842291
StatusSUSPENDED
Start Date2023-06-19
Completion2026-07-30

Brief Summary

We aim to evaluate the safety and efficacy of pBFS-guided high-dose rTMS therapy with short inter-session interval for patients with treatment-resistant depression

Frequently Asked Questions

What is pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression?

pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression is a clinical trial registered under NCT05842291. Current status: SUSPENDED.

What is the status of NCT05842291?

The current status of NCT05842291 (pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression) is: SUSPENDED.

When did pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression start?

pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression started on 2023-06-19.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑